Clean-Fino Chem signs exclusive global HALS supply pact

Clean-Fino Chem Limited signed a July 16, 2026 collaboration with Switzerland-incorporated Genous Chem AG covering exclusive worldwide manufacture and supply of advanced HALS products. The agreement includes minimum offtake and pricing provisions, while warrants exercisable within four years could give Clean-Fino Chem a 25% fully diluted Genous Chem holding.

What did Clean-Fino Chem agree with Genous Chem?

Clean-Fino Chem agreed to a long-term strategic collaboration with Genous Chem on July 16, 2026, for manufacturing and supplying advanced grades of HALS products. The agreement was disclosed in the consolidated results for the quarter and half year ended September 30, 2026, approved by the board on October 31, 2026.

The disclosed arrangement combines a commercial supply relationship with a potential equity interest in Genous Chem. Its commercial terms include worldwide exclusivity, minimum offtake commitments and a pricing mechanism, while its equity component is based on warrants to be issued by Genous Chem.

What does Clean-Fino Chem’s worldwide exclusivity cover?

Clean-Fino Chem’s exclusivity covers manufacturing and supplying the advanced grades of HALS products specified in the July 16 agreement on a worldwide basis. The disclosure does not state product volumes, annual purchase values, manufacturing capacity, customer names or the collaboration’s duration in years beyond describing it as long-term.

The scope is limited to the advanced HALS grades covered by the arrangement. Clean-Fino Chem did not disclose an acquisition of Genous Chem’s intellectual property, distribution network, customer contracts or all HALS products, so the stated exclusivity should not be read beyond the specified manufacturing and supply terms.

Minimum offtake commitments and the pricing mechanism are the two disclosed commercial mechanisms. The filing does not identify which party must meet the minimum offtake, quantify volumes, set out a pricing formula or state whether these terms changed after the product trials completed following September 30, 2026.

How could Clean-Fino Chem obtain a 25% Genous Chem stake?

Clean-Fino Chem could acquire 25% of Genous Chem’s share capital on a fully diluted basis by exercising the warrants that Genous Chem agreed to issue. The warrants may be exercised within four years from their issue date, according to the results disclosure for the half year ended September 30, 2026.

On exercise, Clean-Fino Chem would pay Genous Chem a nominal price per common share. The disclosure does not provide the nominal per-share price, number of warrants, warrant issue date, total payment, voting rights, board representation or any exercise conditions beyond the four-year period.

A potential 25% fully diluted holding is different from a current 25% shareholding. As at the October 31, 2026 disclosure, the reported arrangement was for Genous Chem to issue warrants, and the stated equity position would arise only if Clean-Fino Chem exercises those instruments.

Did Clean-Fino Chem complete the HALS product trials?

Yes, Clean-Fino Chem successfully conducted and completed product trials for the advanced HALS grades after the half year ended September 30, 2026. The October 31, 2026 disclosure did not provide the exact trial-completion date or specify the sites involved.

The timing separates the July 16 agreement from subsequent technical validation. The collaboration was entered into during the six months ending September 30, while the successful trial completion was reported after that reporting date, showing that the trial update was not part of the half-year-end position.

Clean-Fino Chem did not disclose commercial production volumes, first delivery dates, sales from the products, customer qualification results or revised offtake volumes following the completed trials. Nor did it state that the warrants had been exercised or that the potential 25% Genous Chem holding had been acquired.

How does the Genous Chem agreement fit Clean-Fino Chem’s overseas structure?

Clean-Fino Chem’s agreement with the Swiss company was disclosed alongside a separate European corporate step. Through Clean-Fino Chem, the group incorporated Clean Science International B.V. in the Netherlands as part of its initiative to strengthen international presence and support growing business activities in Europe.

The Genous Chem arrangement is framed as worldwide exclusive manufacturing and supply, whereas the Netherlands incorporation is specifically linked to Europe. The disclosure does not say that Clean Science International B.V. is party to the July 16 agreement, will hold the warrants or will manufacture the advanced HALS grades.

The September 30, 2026 review report identifies Clean-Fino Chem as a wholly owned subsidiary and Clean Science International B.V. as a step-down subsidiary. Those relationships describe the group structure, but do not alter the disclosed commercial terms of worldwide exclusivity, minimum offtake commitments, pricing provisions and the four-year warrant window.

Conclusion

Clean-Fino Chem has established a disclosed commercial framework for advanced HALS products through exclusive worldwide manufacturing and supply terms, supported by minimum offtake commitments and a pricing mechanism. The successful completion of product trials after September 30, 2026 adds a technical update, while the potential 25% Genous Chem stake remains conditional on warrant exercise.

The next matter to watch is whether Clean-Fino Chem exercises the warrants within four years of their issue date. Commercial supply volumes, pricing details, initial sales, the warrant issue date and the total exercise payment were not disclosed as of October 31, 2026, while the Netherlands entity is intended to support growing European activities.